Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)

CAPS Rating: 5 out of 5

The Company is engaged in the discovery and development of synthetic DNA and RNA-based compounds for the treatment of cancer, infectious diseases, autoimmune diseases, and asthma/allergies, and for use as vaccine adjuvants.

Recs

0
Player Avatar goldnrtrvrlvr (55.76) Submitted: 5/5/2008 7:24:39 AM : Outperform Start Price: $14.75 IDRA Score: -90.34

New Hi

Featured Broker Partners


Advertisement